Teva, Allergan Settle Rhode Island Opioid Case for $107 Million

Teva Pharmaceuticals and Allergan have agreed to pay a settlement valued at $107 million to the state of Rhode Island over their alleged roles in fueling the opioid epidemic.

Under the terms of the 10-year settlement, the two companies will provide $28.5 million in cash as well as 1 million sprays of Adapt Pharma’s Narcan (naloxone hydrochloride) for the treatment of opioid overdoses, as well as 67,000 30-pill bottles of Indivior’s drug Suboxone (buprenorphine and naloxone) for the treatment of opioid dependence.

“While no amount of money will ever be enough to undo the harm suffered by Rhode Islanders throughout the ongoing opioid epidemic, these additional recoveries will further support public health efforts to respond to the challenges brought on by this epidemic,” said Rhode Island Attorney General Peter F. Neronha.

The companies did not admit to any wrongdoing.